Clostridioides Difficile Colitis

Detailed Overview

C. difficile infection (CDI) typically occurs after disruption of the normal colonic microbiota, most commonly following systemic antibiotic therapy. The organism colonizes the colon and releases Toxin A (an enterotoxin) and Toxin B (a cytotoxin), which disrupt the colonic epithelium, leading to intense inflammation, fluid secretion, and the formation of characteristic inflammatory exudates known as pseudomembranes. Severe cases can progress to toxic megacolon, colonic perforation, and death.

Epidemiology & Demographics

Causes nearly 500,000 infections and 15,000-30,000 deaths annually in the US. The incidence has increased due to the hypervirulent NAP1/BI/027 strain. It primarily affects hospitalized or recently discharged older adults, though community-acquired cases are rising.

Etiological Mechanism

Infection by toxigenic strains of Clostridioides difficile. Spores are ingested via the fecal-oral route, typically from contaminated healthcare environments or the hands of healthcare workers.

Primary Causes

Overgrowth of C. difficile following alteration of normal gut flora

Ingestion of C. difficile spores from contaminated surfaces

• Antibiotic Exposure: Highest risk with clindamycin, fluoroquinolones, cephalosporins, and broad-spectrum penicillins within the past 3 months.
• Advanced Age: Patients >65 years have a significantly higher risk of severe disease and mortality.
• Healthcare Exposure: Recent hospitalization or residence in a long-term care facility.
• Gastric Acid Suppression: Use of Proton Pump Inhibitors (PPIs) reduces gastric acid, allowing spore survival.

Antibiotic use decimates the normal gut microbiome, creating a niche for C. difficile spores (which survive gastric acid) to germinate into vegetative bacteria in the bile-acid-rich environment of the small intestine, and subsequently colonize the colon. The bacteria secrete Toxin A (TcdA) and Toxin B (TcdB). These toxins enter colonic epithelial cells, inactivate Rho family GTPases, causing actin cytoskeleton breakdown, tight junction disruption, and massive apoptosis. This results in profound fluid secretion (diarrhea), neutrophil infiltration, and the formulation of pseudomembranes (yellow-white plaques composed of fibrin, mucin, sloughed apoptotic cells, and leukocytes).

Characteristic Clinical Presentation

• Watery Diarrhea: Usually non-bloody, copious, and frequent (≥3 unformed stools in 24 hours), with a characteristic foul, "horse barn" odor.
• Abdominal Pain: Cramping pain, usually in the lower abdomen.
• Low-grade Fever: Often present, though high fevers (>38.5°C) suggest severe or fulminant disease.
• Nausea and Anorexia: Leading to dehydration and weight loss.

Physical Examination Signs

• Abdominal tenderness to palpation
• Signs of dehydration (dry mucous membranes, tachycardia, poor skin turgor)
• Toxic appearance with abdominal distension (suggests toxic megacolon)

• Toxic Megacolon: Acute, massive colonic dilation with systemic toxicity, risking perforation.
• Colonic Perforation: Leading to peritonitis, sepsis, and requiring emergent colectomy.
• Severe Dehydration and Acute Kidney Injury: Due to massive gastrointestinal fluid losses.
• Recurrent CDI: Occurs in 20-30% of patients after the first episode.

Diagnostic Criteria & Guidelines

Diagnosis requires the presence of clinical symptoms (≥3 unformed stools in 24h) PLUS a positive stool test for C. difficile toxins or toxigenic C. difficile, OR colonoscopic or histopathologic findings of pseudomembranous colitis. Testing should ONLY be done on unformed stool.

Differential Diagnosis

• Antibiotic-associated diarrhea (non-C.difficile)
• Inflammatory Bowel Disease (Ulcerative Colitis or Crohn's flare)
• Ischemic Colitis
• Other infectious enteritides (Salmonella, Shigella, Campylobacter)

Laboratory Tests & Biomarkers

• NAAT/PCR for C. difficile toxin genes: Highly sensitive but cannot distinguish active infection from colonization. Often used in a 2-step algorithm.
• EIA for Glutamate Dehydrogenase (GDH) + EIA for Toxin A/B: GDH detects the organism; Toxin EIA confirms active toxin production.
• Complete Blood Count: Leukocytosis, frequently >15,000/mcL; can exceed 50,000/mcL in severe cases.
• Comprehensive Metabolic Panel: Hypokalemia, elevated BUN/Creatinine indicating pre-renal AKI, hypoalbuminemia.

Imaging Modalities & Findings

• Abdominal CT with IV and PO contrast:
• Flexible Sigmoidoscopy:

• Non-Severe
  WBC ≤15,000 cells/mL and Serum Creatinine <1.5 mg/dL.
• Severe
  WBC >15,000 cells/mL OR Serum Creatinine ≥1.5 mg/dL.
• Fulminant
  Hypotension or shock, ileus, or toxic megacolon.

Second-Line & Adjunctive Therapy

For first recurrence: Fidaxomicin (if Vancomycin used initially) OR prolonged Vancomycin taper/pulse regimen (e.g., 125 mg QID x14 days, then BID x7 days, then daily x7 days, then every 2-3 days for 2-8 weeks). Bezlotoxumab 10 mg/kg IV x1 dose can be added to prevent recurrence in high-risk patients. For multiple recurrences: Fecal Microbiota Transplantation (FMT).

Surgical & Procedural Management

Subtotal colectomy with end-ileostomy for fulminant colitis refractory to medical therapy, toxic megacolon, or colonic perforation.

Recommended Lifestyle Changes

• Strict enteric contact precautions in healthcare settings (Gown and Gloves).
• Hand hygiene MUST be performed with soap and water. Alcohol-based hand sanitizers do NOT kill C. difficile spores.
• Thorough environmental cleaning with EPA-approved spore-killing disinfectants (e.g., bleach).

Patient Counseling & Advice

Inform the patient that diarrhea may take several days to completely resolve even on treatment. Advise strictly washing hands with soap and water after using the restroom. Warn them about the 20-30% risk of recurrence and to contact their doctor if diarrhea returns after completing treatment.

Follow-Up & Monitoring Schedule

Monitor clinical response (stool frequency and consistency). Do NOT re-test stool for 'cure' after treatment, as patients can remain asymptomatically colonized and test positive for weeks to months.

Preventive Strategies

Prudent antimicrobial stewardship (avoiding unnecessary antibiotics). Strict infection control protocols. Minimizing unnecessary PPI use.

Most patients recover with a 10-day course of oral vancomycin or fidaxomicin. However, recurrence is a major challenge. Mortality in fulminant cases or those requiring surgery can exceed 30-40%.